Leftagraph

Every financial statement,
one clean chart.

Search any US-listed company. Data straight from SEC filings.

PROBuild your own list with the screener

ImageneBio, Inc. (IMA) financial statements

Number look wrong? Tell us

Data table
PROBuild your own list with the screener

ImageneBio, Inc. (IMA), most recent 12 months reported: revenue $800K, net loss $52.48M. Latest balance sheet on file: liquid cash $136.15M. From SEC filings. Others in Biological Products, (No Diagnostic Substances): SCINAI IMMUNOTHERAPEUTICS LTD. · INHIBRX BIOSCIENCES, INC. · Pluri Inc. · ProKidney Corp. · CARDIFF ONCOLOGY, INC. · aTYR PHARMA INC · VivoSim Labs, Inc. · AIM ImmunoTech Inc.

Stock screener

Watchlist